✦ LIBER ✦

The transplantable adrenocortical carcinoma of the rat — Snell 494 — Following treatment with op-DDD and cyclophosphamide

✍ Scribed by R. Krüger; K. H. Voigt; G. Dhom

Book ID: 112785770
Publisher: Springer-Verlag
Year: 1986
Tongue: English
Weight: 133 KB
Volume: 111
Category: Article
ISSN: 1432-1335
DOI: 10.1007/bf02580321

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Impact of monitoring plasma 1,1-dichloro

Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma

✍ E. Baudin; G. Pellegriti; M. Bonnay; A. Penfornis; A. Laplanche; G. Vassal; M. S 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 2 views

Radiobiological hypoxia of a transplante

Radiobiological hypoxia of a transplanted rat tumour and the effect of treatment with cyclophosphamide

✍ Bryan Dixon; James V. Moore; Helen Speakman 📂 Article 📅 1978 🏛 Elsevier Science ⚖ 393 KB

Autologous bone marrow transplantation f

Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature

✍ Stahel, Rolf A.; Takvorian, Ronald W.; Skarin, Arthur T.; Canellos, George P. 📂 Article 📅 1984 🏛 Elsevier Science ⚖ 568 KB

Long-term follow-up of a phase I study o

Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias

✍ Marcos de Lima; Farhad Ravandi; Munir Shahjahan; Borje Andersson; Daniel Couriel 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 2 views

## Abstract ## BACKGROUND Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. ## METHODS Patients with high‐ris

Augmented high dose cyclophosphamide, et

Augmented high dose cyclophosphamide, etoposide, and carmustine followed by transplantation with peripheral blood stem cells (PBSC) in the treatment of relapsed or refractory Hodgkin’s disease

✍ J.E. Schwartz; M.J. Robertson; K.G. Cornetta; L.D. Cripe; R.P. Nelson; C.T. Yian 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 76 KB

Chemotherapy with maximally tolerable do

Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors

✍ Mulder, Paula O.M.; G.E. de Vries, Elisabeth; Koops, Heimen Schraffordt; Splinte 📂 Article 📅 1988 🏛 Elsevier Science ⚖ 581 KB